KPTI · Karyopharm Therapeutics Inc. · Executive Compensation
$0.67
-0.14 (-16.99%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$36.74M
Shares
22.68M
Volume · Oct 5
954.48K
Avg daily vol (3M)
1.66M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $2,320,902 |
| Reshma Rangwala | Chief Medical Officer and Head of Research | $2,016,134 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,399,580 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $2,069,341 |
| Reshma Rangwala | Chief Medical Officer and Head of Research | $1,124,444 |
| Sohanya Cheng | Chief Commercial Officer and Head of Business Development | $1,094,829 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $2,626,288 |
| Reshma Rangwala | Chief Medical Officer and Head of Research | $1,227,789 |
| Sohanya Cheng | Chief Commercial Officer and Head of Business Development | $1,193,414 |
| Michael Mason | Chief Financial Officer | $1,139,312 |
| Stuart Poulton | — | $1,109,115 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $6,910,015 |
| Sharon Shacham | — | $6,037,789 |
| Michael Mason | Chief Financial Officer | $2,699,032 |
| Sohanya Cheng | — | $2,612,718 |
| Chief Commercial | Officer | $2,612,718 |
| Ran Frenkel | — | $2,160,250 |
| Michael Mano | — | $2,060,407 |
| Chief Development | Officer | $1,795,247 |
| Stuart Poulton | — | $1,779,848 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $8,355,172 |
| Sharon Shacham | Ph.D., M.B.A. | $3,106,591 |
| Michael Kauffman | M.D., Ph.D. | $3,069,589 |
| Michael Mason | Chief Financial Officer | $1,744,578 |
| Jatin Shah | Former Executive Vice President, Chief Medical Officer | $1,588,213 |
| Ran Frenkel | RPh. Executive Vice President, Chief Development Officer | $1,577,203 |
| Former Chief | Development Officer | $1,577,203 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Senior Clinical | Advisor and Former Chief Executive Officer | $3,937,039 |
| Michael Kauffman | M.D., Ph.D. Chief Executive Officer | $3,937,039 |
| Former Chief | Scientific Officer | $3,670,884 |
| Chief Scientific | Officer and Former President | $3,670,884 |
| Sharon Shacham | Ph.D., M.B.A. President and ChiefScientific Officer | $3,670,884 |
| Michael Mason | Chief Financial Officer | $2,266,816 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Senior Clinical | Advisor and Former Chief Executive Officer | $3,231,504 |
| Michael Kauffman | M.D., Ph.D. Chief Executive Officer | $3,231,504 |
| Sharon Shacham | Ph.D., M.B.A. President and ChiefScientific Officer | $3,020,459 |
| Chief Scientific | Officer and Former President | $3,020,459 |
| Christopher Primiano | J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | $1,623,347 |
| Michael Mason | M.B.A., C.P.A. Executive Vice President, Chief Financial Officer and Treasurer | $956,697 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Kauffman | M.D., Ph.D. Chief Executive Officer | $2,274,945 |
| Sharon Shacham | Ph.D., M.B.A. President and Chief Scientific Officer | $2,089,383 |
| Christopher Primiano | J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | $1,522,593 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christy J. Oliger | Class I director | Appointed | 2026-05-28 |
| Barry E. Greene | Class I director | Appointed | 2026-05-28 |
| Mansoor Raza Mirza, M.D. | member of the Board of Directors | Resigned | 2025-09-11 |
| Zhen Su, M.D., M.B.A. | Class III director | Appointed | 2025-05-29 |
| Garen G. Bohlin | Class III director | Appointed | 2025-05-29 |
| Lori Macomber | Executive Vice President, Chief Financial Officer and Treasurer | Appointed | 2025-01-02 |
| Kristin Abate | Vice President, Chief Accounting Officer, and Assistant Treasurer | Appointed | 2024-11-20 |
| Michael Mason | Executive Vice President, Chief Financial Officer and Treasurer | Resigned | 2024-08-29 |
| Chen Schor | Class II director | Appointed | 2024-05-31 |
| Richard Paulson | Class II director | Appointed | 2024-05-31 |
| Deepika R. Pakianathan | Class II director | Appointed | 2024-05-31 |
| Peter K Honig, M.D., MPH | member of the Board of Directors | Resigned | 2023-12-08 |
| Zhen Su, M.D., M.B.A | independent director | Appointed | 2023-09-01 |
| Christy J. Oliger | Class I director | Appointed | 2023-05-25 |
| Mansoor Raza Mirza M.D. | Class I director | Appointed | 2023-05-25 |
| Barry E. Greene | Class I director | Appointed | 2023-05-25 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | Appointed | 2022-07-28 |
| Ran Frenkel | Executive Vice President, Chief Development Officer | Resigned | 2022-07-28 |